[go: up one dir, main page]

WO2005044824A3 - Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin - Google Patents

Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin Download PDF

Info

Publication number
WO2005044824A3
WO2005044824A3 PCT/IB2004/003571 IB2004003571W WO2005044824A3 WO 2005044824 A3 WO2005044824 A3 WO 2005044824A3 IB 2004003571 W IB2004003571 W IB 2004003571W WO 2005044824 A3 WO2005044824 A3 WO 2005044824A3
Authority
WO
WIPO (PCT)
Prior art keywords
highly pure
preparation
cephalosporin
processes
substituted vinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/003571
Other languages
French (fr)
Other versions
WO2005044824A2 (en
Inventor
Yatendra Kumar
Mohan Prasad
Kaptan Singh
Ashok Prasad
Santosh Richhariya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to EP04798757A priority Critical patent/EP1689755A2/en
Priority to JP2006538976A priority patent/JP2007510709A/en
Publication of WO2005044824A2 publication Critical patent/WO2005044824A2/en
Publication of WO2005044824A3 publication Critical patent/WO2005044824A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention relates to a process for preparation of highly pure amorphous and crystalline forms of cefditoren pivoxil and pharmaceutical compositions comprising highly pure amorphous and crystalline forms of cefditoren pivoxil. The present invention also relates to a method of treating infections using highly pure amorphous and crystalline forms of cefditoren pivoxil. The highly pure cefditoren pivoxil has a purity greater than 98.5% and contains less than 1.0% of the E-isomer impurity and less than 1 % of the Δ2­isomer impurity.
PCT/IB2004/003571 2003-11-07 2004-11-01 Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin Ceased WO2005044824A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04798757A EP1689755A2 (en) 2003-11-07 2004-11-01 Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
JP2006538976A JP2007510709A (en) 2003-11-07 2004-11-01 Method for producing high purity 3- (2-substituted vinyl) cephalosporin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1368DE2003 2003-11-07
IN1368/DEL/2003 2003-11-07

Publications (2)

Publication Number Publication Date
WO2005044824A2 WO2005044824A2 (en) 2005-05-19
WO2005044824A3 true WO2005044824A3 (en) 2005-07-14

Family

ID=34566866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003571 Ceased WO2005044824A2 (en) 2003-11-07 2004-11-01 Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin

Country Status (5)

Country Link
EP (1) EP1689755A2 (en)
JP (1) JP2007510709A (en)
CN (1) CN1902207A (en)
AR (1) AR046229A1 (en)
WO (1) WO2005044824A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003141A2 (en) 2003-07-04 2005-01-13 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of cefditoren
WO2006024900A1 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Highly pure cefditoren pivoxil
EP1954653A4 (en) * 2005-11-23 2010-11-03 Merck Sharp & Dohme PROCESS FOR GENERATING AMORPHOUS SOLID FOR PHARMACEUTICAL AGENTS INSOLUBLED IN WATER
CN101560216B (en) * 2009-05-27 2011-06-15 上海交通大学 Method for preparing cefditoren pivoxil
KR101561963B1 (en) * 2013-05-23 2015-10-22 영진약품공업 주식회사 Novel crystalline from of cefditoren pivoxyl and preparation method thereof
CN106117244B (en) * 2016-06-24 2018-10-19 瑞阳制药有限公司 The process for purification of Cefditoren pivoxil Cephalosporins
CN106243128B (en) * 2016-07-30 2018-09-04 济南康和医药科技有限公司 A kind of process for purification of Cefditoren pivoxil Cephalosporins
CN107422056B (en) * 2017-08-17 2020-04-24 山东裕欣药业有限公司 Gas chromatography detection method of iodomethyl pivalate and preparation method thereof
CN109053768A (en) * 2018-08-07 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 A kind of preparation method of unformed cefditoren
CN109336904B (en) * 2018-11-21 2020-06-09 山东罗欣药业集团股份有限公司 Preparation method of cefditoren pivoxil
CN110251467A (en) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 A kind of preparation method of amorphous state Cefditoren pivoxil Cephalosporins composition
CN116332956A (en) * 2023-01-16 2023-06-27 浙江东邦药业有限公司 Preparation method of amorphous cefditoren pivoxil

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same
EP1051978A1 (en) * 1998-01-07 2000-11-15 Meiji Seika Kaisha, Ltd. Crystallographically stable amorphous cephalosporin compositions and process for producing the same
JP2001131071A (en) * 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd Amorphous substance and medical composition containing amorphous substance

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012200A1 (en) * 1996-09-20 1998-03-26 Meiji Seika Kaisha Ltd. A crystalline substance of cefditoren pivoxyl and the production of the same
US6294669B1 (en) * 1996-09-20 2001-09-25 Meiji Seika Kaisha Ltd. Crystalline substance of cefditoren pivoxyl and the production of the same
US20020002279A1 (en) * 1996-09-20 2002-01-03 Kiyoshi Yasui Crystalline substance of cefditoren pivoxyl and the production of the same
EP1051978A1 (en) * 1998-01-07 2000-11-15 Meiji Seika Kaisha, Ltd. Crystallographically stable amorphous cephalosporin compositions and process for producing the same
US6342493B1 (en) * 1998-01-07 2002-01-29 Meiji Seika Kaisha Ltd. Crystallographically stable amorphous cephalosporin compositions and process for producing the same
US20020037322A1 (en) * 1998-01-07 2002-03-28 Masahiro Onodera Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof
JP2001131071A (en) * 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd Amorphous substance and medical composition containing amorphous substance

Also Published As

Publication number Publication date
EP1689755A2 (en) 2006-08-16
JP2007510709A (en) 2007-04-26
AR046229A1 (en) 2005-11-30
CN1902207A (en) 2007-01-24
WO2005044824A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2005044824A3 (en) Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
HUP0201646A3 (en) Novel alpha-amino acid derivatives, process for producing them and pharmaceutical compositions containing them
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
UA97161C2 (en) Normal;heading 1;heading 2;heading 3;PHARMACEUTICAL COMPOSITION CONTAINING DIHYDROPYRIDINE CALCIUM CHANNEL ANTAGONIST AND METHOD FOR THE PREPARATION THEREOF
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2005062897A3 (en) Polymorphs of ezetimibe and processes for the preparation thereof
IL162461A0 (en) Polymorphs of clopidogrel hydrogensulfate
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
WO2005061467A3 (en) Piperazine derivatives as bradykinin antagonists
JO2216B1 (en) 5-chloro-3-(4 methanesulfonylphenyl)-6 methyl-(2.3) bipyridinly in pure crystalline form and process for synthesis
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
AU3184300A (en) Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil
WO2002080857A8 (en) Polymorphs of fexofenadine hydrochloride
MY142129A (en) Amorphous lercanidipine hydrochloride
WO2005007642A3 (en) Novel azaheterocyclic amides useful for treating pain
WO2007075838A3 (en) Pure and stable tiotropium bromide
WO2006035433A3 (en) Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
BG107407A (en) Novel polymorph v of torasemide
AU2002367896A1 (en) Process for the preparation of ceftiofur acid
AU2003250522A1 (en) Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2001070694A8 (en) Amorphous torasemide modification
WO2004078115A3 (en) Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480039756.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006538976

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3103/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004798757

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004798757

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004798757

Country of ref document: EP